Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations
- 25 October 2004
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 101 (50), 17456-17461
- https://doi.org/10.1073/pnas.0407061101
Abstract
Protein kinase inhibitors can be effective in treating selected cancers, but most suppress several kinases. Imatinib mesylate has been useful in the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia and B cell acute lymphoblastic leukemia through the inhibition of BCR-ABL tyrosine kinase activity. Imatinib mesylate has also been shown to inhibit KIT, ARG, and platelet-derived growth factor receptors α and β, and potentially other tyrosine kinases. We have produced a mutant allele of BCR-ABL (T315A) that is uniquely inhibitable by the small molecule 4-amino-1-tert-butyl-3-(1-naphthyl)pyrazolo[3,4-d]pyrimidine and used it to demonstrate that sole suppression of BCR-ABL activity was insufficient to eliminate BCR-ABL+ KIT+-expressing immature murine myeloid leukemic cells. In contrast, imatinib mesylate effectively eliminated BCR-ABL+ KIT+-expressing leukemic cells. In the cellular context of mature myeloid cells and Pro/Pre B cells that do not express KIT, monospecific BCR-ABL inhibition was quantitatively as effective as imatinib mesylate in suppressing cell growth and inducing apoptosis. These results suggest that the therapeutic effectiveness of small molecule drugs such as imatinib mesylate could be due to the inhibitor's ability to suppress protein kinases in addition to the dominant target.Keywords
This publication has 40 references indexed in Scilit:
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Phosphoinositide 3-kinase signaling is essential for ABL oncogene–mediated transformation of B-lineage cellsBlood, 2004
- Critical Role for Kit-mediated Src Kinase But Not PI 3-Kinase Signaling in Pro T and Pro B Cell DevelopmentThe Journal of Experimental Medicine, 2004
- Cell context–specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitorsBlood, 2003
- The roles of FLT3 in hematopoiesis and leukemiaBlood, 2002
- Protein Engineering of Protein Kinase A Catalytic Subunits Results in the Acquisition of Novel Inhibitor SensitivityJournal of Biological Chemistry, 2002
- BCR–ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factorOncogene, 2002
- Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia – potential clinical significanceLeukemia, 2002
- Cancer Cell CyclesScience, 1996
- Interaction of the receptor tyrosine kinase p145
c‐
kit
with the p210
bcr/abl
kinase in myeloid cellsBritish Journal of Haematology, 1996